Canaccord Genuity Group Issues Positive Forecast for AxoGen (NASDAQ:AXGN) Stock Price

AxoGen (NASDAQ:AXGN) had its target price upped by Canaccord Genuity Group from $50.00 to $55.00 in a report issued on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the medical equipment provider’s stock.

A number of other research firms also recently weighed in on AXGN. Truist Financial set a $55.00 price target on AxoGen in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Jefferies Financial Group reissued a “buy” rating and issued a $55.00 price objective on shares of AxoGen in a research report on Wednesday. Raymond James Financial restated an “outperform” rating and set a $48.00 target price on shares of AxoGen in a report on Wednesday, April 29th. Finally, Lake Street Capital raised their target price on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

AxoGen Stock Performance

Shares of AxoGen stock opened at $41.35 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -60.81 and a beta of 1.09. The stock’s 50-day moving average is $42.10 and its 200-day moving average is $37.33. AxoGen has a one year low of $12.39 and a one year high of $46.95.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 10.13% and a negative net margin of 13.36%.The business had revenue of $69.73 million during the quarter, compared to the consensus estimate of $67.10 million. Equities analysts predict that AxoGen will post -0.37 earnings per share for the current fiscal year.

Insider Transactions at AxoGen

In related news, Director Kathy Johnson Weiler sold 16,344 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $44.09, for a total transaction of $720,606.96. Following the transaction, the director directly owned 16,344 shares in the company, valued at approximately $720,606.96. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy Mcbride Wendell sold 1,647 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total transaction of $70,162.20. Following the sale, the director directly owned 93,826 shares in the company, valued at $3,996,987.60. This trade represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 29,041 shares of company stock worth $1,268,792 in the last 90 days. Corporate insiders own 2.44% of the company’s stock.

Institutional Trading of AxoGen

A number of large investors have recently added to or reduced their stakes in the company. MCF Advisors LLC bought a new position in shares of AxoGen in the 4th quarter valued at about $30,000. Arax Advisory Partners raised its holdings in shares of AxoGen by 362.4% in the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 819 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of AxoGen in the 4th quarter valued at about $36,000. Kestra Advisory Services LLC bought a new stake in shares of AxoGen in the 4th quarter valued at about $39,000. Finally, KBC Group NV acquired a new stake in AxoGen in the 1st quarter valued at about $41,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen raised its 2026 outlook, citing momentum in breast reconstruction and continued demand for its peripheral nerve repair products. The improved outlook suggests management sees stronger revenue potential than previously expected. AxoGen Is Up After Raising 2026 Outlook
• Positive Sentiment: Second-quarter revenue reached $69.73 million, exceeding analyst expectations of $67.10 million. Adjusted earnings of $0.12 per share also topped the Zacks consensus estimate of $0.09 and matched the broader analyst consensus. AxoGen Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Canaccord Genuity raised its price target from $50 to $55 and reiterated a “buy” rating. Citizens JMP also lifted its target to $55 and maintained a “market outperform” rating, signaling increased confidence in AxoGen’s growth prospects. Analyst Price Target Revisions
• Neutral Sentiment: The earnings report showed strong revenue growth, but conference-call commentary highlighted ongoing margin challenges as AxoGen invests for expansion.
• Negative Sentiment: AxoGen continues to report negative profitability metrics, including a net loss and negative net margin and return on equity. Investors may therefore remain focused on whether the stronger outlook translates into sustainable earnings growth.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.